Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.40 |
| ▸ | INSR | P06213 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.38 |
| ▸ | MTOR | P42345 | 5/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.38 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350535 | 0.94 | SYK (0.41) | SYKJAK2KDRAURKB | |
| SCHEMBL1306157 | 0.89 | INSR (0.51) | ALKINSRKDRAURKB | |
| SCHEMBL1305373 | 0.82 | INSR (0.43) | ALKINSR | |
| SCHEMBL1305751 | 0.81 | JAK2 (0.44) | SYKALKINSRJAK2TBK1 | |
| SCHEMBL352309 | 0.80 | SYK (0.42) | SYKKDRAURKB | |
| SCHEMBL352724 | 0.80 | SYK (0.37) | SYKALKJAK2KDRAURKB | |
| SCHEMBL1305758 | 0.75 | SYK (0.42) | SYKJAK2KDRAURKB | |
| SCHEMBL4411964 | 0.75 | TTBK1 (0.49) | SYKINSRJAK2TBK1KDR | |
| SCHEMBL351023 | 0.74 | ADORA3 (0.45) | SYKJAK2KDR | |
| SCHEMBL10171163 | 0.72 | JAK3 (0.60) | SYKPIK3CBTTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960372-B1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | claimed |
| EP-1960372-A1 | KINASE INHIBITORS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2007070872-A1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | MIDCAP FINANCIAL TRUST | 2016-01-28 | — | — | US | disclosed |
| US-9096542-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | SYK 2/4885ALK 230/4885INSR 996/4885 |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | SYK 2/4885ALK 230/4885INSR 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.